Reuters logo
BRIEF-Sangamo Therapeutics receives orphan drug designation from the FDA for SB-318 genome editing treatment for MPS I
January 11, 2017 / 12:43 PM / 8 months ago

BRIEF-Sangamo Therapeutics receives orphan drug designation from the FDA for SB-318 genome editing treatment for MPS I

Jan 11 (Reuters) - Sangamo Therapeutics Inc

* Sangamo Therapeutics receives orphan drug designation from the FDA for SB-318 genome editing treatment for MPS I

* Sangamo Therapeutics says data from studies and from planned clinical trial for a fourth lead program, SB-525 are expected in late 2017 or early 2018

* Sangamo Therapeutics says in 2017, plans to conduct first in vivo genome editing clinical trials including phase 1/2 studies for three programs Source text for Eikon: Further company coverage:

Our Standards:The Thomson Reuters Trust Principles.
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below